Streptokinase for Injection

What is Streptokinase for Injection?
Streptokinase for Injection is a powerful thrombolytic agent (often called a "clot-buster") derived from Beta-hemolytic streptococci. It is a life-saving medication used in emergency medicine to dissolve blood clots that have formed in the blood vessels. By clearing these obstructions, it restores vital blood flow to organs such as the heart and lungs, preventing permanent tissue damage and improving survival rates in acute cardiovascular events.
Uses of Streptokinase for Injection
Acute Myocardial Infarction (Heart Attack): To dissolve clots in the coronary arteries and limit heart muscle damage.
Pulmonary Embolism: Treatment of massive or life-threatening blood clots in the lungs.
Deep Vein Thrombosis (DVT): Management of extensive clots in the deep veins of the legs.
Acute Arterial Thromboembolism: To clear blockages in the peripheral arteries to prevent limb loss.
Arteriovenous Cannula Occlusion: To clear clotted hemodialysis cannulas and restore access.
How Does Streptokinase for Injection Work?
Streptokinase works by forming a complex with plasminogen, a precursor protein found in the blood. This complex then converts free plasminogen into plasmin, an active enzyme that breaks down fibrin—the main structural protein that holds a blood clot together. This enzymatic "digestion" of the fibrin mesh effectively dissolves the clot and restores circulation.
FAQs on Streptokinase for Injection
1. How soon must Streptokinase be administered during a heart attack? For maximum benefit, Streptokinase should be administered as soon as possible after the onset of symptoms, ideally within the first 6 to 12 hours. The earlier the "clot-busting" begins, the more heart muscle can be saved from permanent damage.
2. Can Streptokinase be used multiple times for the same patient? Caution is required. Because it is derived from bacteria, the body may develop antibodies against Streptokinase. If a patient is treated with it again between 5 days and 12 months after the first dose, the drug may be less effective or cause an allergic reaction.
3. What is the most significant risk associated with this treatment? The primary risk is bleeding (hemorrhage). Because the drug dissolves clots throughout the entire body, not just at the site of the blockage, patients must be closely monitored for signs of internal bleeding, especially in the gastrointestinal tract or the brain.
Therapeutic Category
Cardiovascular (Thrombolytic Agent)
Looking for a reliable Streptokinase for Injection manufacturer? Contact Farbe Firma Pvt. Ltd. for dossier support, registration assistance, and export supplies. We provide high-potency cardiovascular injectables manufactured under strict WHO-GMP conditions.